Experienced in Small Cell Lung Cancer (SCLC)

Sophie E. Schneider

Bern, BE, CH 
Experienced in Small Cell Lung Cancer (SCLC)
Bern, BE, CH 
OverviewLocationsClinical Research

Overview

Sophie Schneider practices in Bern, Switzerland. Ms. Schneider is rated as an Experienced expert by MediFind in the treatment of Small Cell Lung Cancer (SCLC). Her top areas of expertise are Primary Lateral Sclerosis, Lung Cancer, Cerebral Hypoxia, Spinal Muscular Atrophy Type 2, and Hysterectomy.

Her clinical research consists of co-authoring 37 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Small Cell Lung Cancer (SCLC).

Gender
Female

Locations

Bern, BE 3010, Switzerland
Other Locations
Basel, BS, Switzerland
Zurich, ZH 8001, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Other
Study Drug: Adjuvant Chemotherapy
Study Phase: Not Applicable
A Phase II, Multi-centre Study, to Evaluate the Efficacy and Safety of Osimertinib Treatment for Patients with EGFR-mutated Non-small Cell Lung Cancer (NSCLC) with Brain or Leptomeningeal Metastases
A Phase II, Multi-centre Study, to Evaluate the Efficacy and Safety of Osimertinib Treatment for Patients with EGFR-mutated Non-small Cell Lung Cancer (NSCLC) with Brain or Leptomeningeal Metastases
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug
Study Drug: Osimertinib
Study Phase: Phase 2
View 1 Less Clinical Trial

37 Total Publications

Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020.
Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020.
Journal: NEJM evidence
Published: June 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Schneider's expertise for a condition
ConditionClose
        View All 12 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile